Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 1

Status

Recruiting 16Active not recruiting 6Not yet recruiting 4Terminated 3Withdrawn 2Completed 2Approved for marketing 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 6Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Urothelial Bladder Carcinoma 1Solid Tumor 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Lung Neoplasms 1Klatskin Tumor 1HRD Cancer 1Cholangiocarcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 15Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6Albumin-Bound Paclitaxel 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Epirubicin 5130-nm albumin-bound paclitaxel 5capivasertib 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Blood Specimen Collection 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × sacituzumab govitecan × Clear all
NCT04595565 2026-04-22

SASCIA

GBG Forschungs GmbH

Phase 3 Active not recruiting
1,332 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting
145 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Gilead Sciences

Phase 3 Active not recruiting
623 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Gilead Sciences

Phase 2 Active not recruiting
80 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Gilead Sciences

Phase 3 Active not recruiting
443 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05101096 2025-03-25

ASCENT-J02

Gilead Sciences

Phase 1/2 Active not recruiting
135 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡